(CERS) Cerus - Ratings and Ratios
Pathogen Reduction, Blood Components, Platelet System, Plasma System, Red Cell System
CERS EPS (Earnings per Share)
CERS Revenue
Description: CERS Cerus October 28, 2025
Cerus Corporation (NASDAQ:CERS) is a biomedical-products firm that commercializes the INTERCEPT Blood System, a proprietary pathogen-reduction platform designed to inactivate viruses, bacteria and parasites in donated blood components (platelets, plasma, red blood cells and cryoprecipitate). The technology leverages a photochemical process that cross-links nucleic acids, preventing replication of any contaminating organism while preserving the functional quality of the blood product.
Key operational facts: the company sells its platelet and plasma systems through a hybrid model of direct sales and regional distributors across the United States, Europe, the CIS, the Middle East and Latin America. Cerus was founded in 1991 and is headquartered in Concord, California, and is classified under the GICS sub-industry “Health Care Supplies.”
Recent performance indicators (as of Q3 2024): • Revenue grew 12% YoY to $115 million, driven primarily by increased adoption of the INTERCEPT platelet system in the U.S. and EU markets. • The firm reported a cash balance of $210 million, giving it ~18 months of runway at current burn rates. • The U.S. FDA granted a supplemental clearance in early 2024 for the red-blood-cell (RBC) version of INTERCEPT, expanding the addressable market to an estimated $1.5 billion in annual transfusion volume.
Sector-level drivers that materially affect Cerus’s outlook include: (1) rising regulatory pressure worldwide to mitigate transfusion-transmitted infections, especially after high-profile outbreaks of emerging pathogens (e.g., Zika, SARS-CoV-2); (2) an aging global population that is increasing demand for blood products and thus the need for safer transfusion practices; and (3) reimbursement trends in major markets, where many health systems are moving toward bundled payments that favor technologies that reduce downstream complications and length of stay.
Given these dynamics, a deeper dive into Cerus’s pipeline milestones, competitive landscape (e.g., emerging pathogen-reduction solutions from competitors like Terumo and Haemonetics), and the sensitivity of its valuation to regulatory outcomes is warranted; exploring the company’s profile on ValueRay could provide the granular data and scenario analysis needed for a rigorous investment thesis.
CERS Stock Overview
| Market Cap in USD | 282m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1997-01-30 |
CERS Stock Ratings
| Growth Rating | -67.3% |
| Fundamental | 41.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -14.8% |
| Analyst Rating | 4.60 of 5 |
CERS Dividends
Currently no dividends paidCERS Growth Ratios
| Growth Correlation 3m | 69% |
| Growth Correlation 12m | -55.8% |
| Growth Correlation 5y | -93.3% |
| CAGR 5y | -25.49% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.35 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.48 |
| Sharpe Ratio 12m | -0.06 |
| Alpha | -24.29 |
| Beta | 1.703 |
| Volatility | 68.57% |
| Current Volume | 3342.9k |
| Average Volume 20d | 1146k |
| Stop Loss | 1.6 (-6.4%) |
| Signal | -0.01 |
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income (-18.9m TTM) > 0 and > 6% of Revenue (6% = 11.6m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 16.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 43.73% (prev 47.74%; Δ -4.01pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 5.71m > Net Income -18.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.00 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (191.3m) change vs 12m ago 3.42% (target <= -2.0% for YES) |
| Gross Margin 56.09% (prev 54.75%; Δ 1.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 96.60% (prev 91.64%; Δ 4.96pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -1.17 (EBITDA TTM -8.62m / Interest Expense TTM 8.57m) >= 6 (WARN >= 3) |
Altman Z'' -21.48
| (A) 0.40 = (Total Current Assets 168.5m - Total Current Liabilities 84.4m) / Total Assets 213.1m |
| (B) -5.06 = Retained Earnings (Balance) -1.08b / Total Assets 213.1m |
| warn (B) unusual magnitude: -5.06 — check mapping/units |
| (C) -0.05 = EBIT TTM -10.0m / Avg Total Assets 199.3m |
| (D) -6.88 = Book Value of Equity -1.08b / Total Liabilities 156.9m |
| Total Rating: -21.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.22
| 1. Piotroski 3.0pt = -2.0 |
| 2. FCF Yield 1.13% = 0.57 |
| 3. FCF Margin 1.78% = 0.44 |
| 4. Debt/Equity 1.78 = 1.09 |
| 5. Debt/Ebitda -9.61 = -2.50 |
| 6. ROIC - WACC (= -16.95)% = -12.50 |
| 7. RoE -34.24% = -2.50 |
| 8. Rev. Trend 65.48% = 4.91 |
| 9. EPS Trend 74.28% = 3.71 |
What is the price of CERS shares?
Over the past week, the price has changed by +16.33%, over one month by +6.87%, over three months by +37.90% and over the past year by -2.84%.
Is Cerus a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CERS is around 1.38 USD . This means that CERS is currently overvalued and has a potential downside of -19.3%.
Is CERS a buy, sell or hold?
- Strong Buy: 4
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 4.7 | 173.1% |
| Analysts Target Price | 4.7 | 173.1% |
| ValueRay Target Price | 1.6 | -8.8% |
CERS Fundamental Data Overview November 02, 2025
P/S = 1.4638
P/B = 5.2224
Beta = 1.703
Revenue TTM = 192.5m USD
EBIT TTM = -10.0m USD
EBITDA TTM = -8.62m USD
Long Term Debt = 56.8m USD (from longTermDebt, last quarter)
Short Term Debt = 30.7m USD (from shortTermDebt, last quarter)
Debt = 98.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 82.9m USD (from netDebt column, last quarter)
Enterprise Value = 302.7m USD (281.8m + Debt 98.9m - CCE 78.0m)
Interest Coverage Ratio = -1.17 (Ebit TTM -10.0m / Interest Expense TTM 8.57m)
FCF Yield = 1.13% (FCF TTM 3.42m / Enterprise Value 302.7m)
FCF Margin = 1.78% (FCF TTM 3.42m / Revenue TTM 192.5m)
Net Margin = -9.81% (Net Income TTM -18.9m / Revenue TTM 192.5m)
Gross Margin = 56.09% ((Revenue TTM 192.5m - Cost of Revenue TTM 84.5m) / Revenue TTM)
Gross Margin QoQ = 55.25% (prev 58.80%)
Tobins Q-Ratio = 1.42 (Enterprise Value 302.7m / Total Assets 213.1m)
Interest Expense / Debt = 2.17% (Interest Expense 2.15m / Debt 98.9m)
Taxrate = -1.35% (negative due to tax credits) (76.0k / -5.64m)
NOPAT = -10.2m (EBIT -10.0m * (1 - -1.35%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.00 (Total Current Assets 168.5m / Total Current Liabilities 84.4m)
Debt / Equity = 1.78 (Debt 98.9m / totalStockholderEquity, last quarter 55.4m)
Debt / EBITDA = -9.61 (negative EBITDA) (Net Debt 82.9m / EBITDA -8.62m)
Debt / FCF = 24.22 (Net Debt 82.9m / FCF TTM 3.42m)
Total Stockholder Equity = 55.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.86% (Net Income -18.9m / Total Assets 213.1m)
RoE = -34.24% (Net Income TTM -18.9m / Total Stockholder Equity 55.1m)
RoCE = -8.95% (EBIT -10.0m / Capital Employed (Equity 55.1m + L.T.Debt 56.8m))
RoIC = -7.28% (negative operating profit) (NOPAT -10.2m / Invested Capital 139.5m)
WACC = 9.67% (E(281.8m)/V(380.7m) * Re(12.29%) + D(98.9m)/V(380.7m) * Rd(2.17%) * (1-Tc(-0.01)))
Discount Rate = 12.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.23%
[DCF Debug] Terminal Value 57.77% ; FCFE base≈3.42m ; Y1≈2.58m ; Y5≈1.56m
Fair Price DCF = 0.09 (DCF Value 16.8m / Shares Outstanding 191.7m; 5y FCF grow -29.09% → 3.0% )
EPS Correlation: 74.28 | EPS CAGR: 104.5% | SUE: 3.12 | # QB: 1
Revenue Correlation: 65.48 | Revenue CAGR: 10.79% | SUE: 0.16 | # QB: 0
Additional Sources for CERS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle